The present invention pertains to a process for the preparation of an orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a disorder of the human subject, comprising the steps of providing a fluid formulation comprising the medicinal substance, providing a solid element having formed therein at least one cavity, cooling the solid element to a temperature below a freezing temperature of the formulation, filling the cavity with the fluid formulation, solidifying the formulation while present in the cavity by extracting heat from the formulation through a cavity wall by conduction, to form a solid pellet comprising the medicinal substance without actively shaping the entire surface of the pellet, taking the pellet out of the cavity, and drying the pellet in a vacuum to obtain the tablet. The invention also pertains to the tablet itself and a package comprising such a tablet.
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U))
— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(Hi))

Published:
— with international search report (Art. 21(3))
Process to form an orally disintegrating tablet for human use

GENERAL FIELD OF THE INVENTION

The present invention pertains to a process for the preparation of an orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a disorder of the human subject.

BACKGROUND OF THE INVENTION

Orally disintegrating tablets (ODT's), also called melt-in-mouth, fast-melting, mouth-dissolving, rapid-melt, orodispersible or quickly dissolving tablets are solid dosage forms that rapidly disintegrate in the oral human cavity without taking water. They thus overcome for example swallowing problems (especially for geriatric and paediatric patients) and may improve patient compliance. When an ODT is placed in the mouth, saliva causes it to disintegrate rapidly (usually within 60 seconds, preferably within 30 seconds and more preferably within 10 seconds) and to disperse the dosage form so that the saliva contains the medicinal substance. The patient either swallows the saliva-substance mixture such that it reaches the stomach, or a larger part (if not all) of the medicinal substance is absorbed through the mouth, pharynx and/or esophagus before it reaches the stomach, thus preventing first pass metabolism of the medicinal substance, and therewith enhancing the bioavailability of it. A variety of medicinal substances and/or combinations thereof can be used as the active ingredient in the ODT such as for example analgesics and anti-inflammatory agents, antacids, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-coagulants, anti-depressants, anti-diabetics, anti-diarrheals, anti-epileptics, anti-fungal agents, anti-gout agents, anti-histamines, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents and immunosuppressants, anti-psychotics, anti/protozoal agents, anti-rheumatics, anti-thyroid agents, anti-viral agents, anxiolytics, sedatives, hypnotics and neuroleptics, beta-blockers, cardiac inotropic agents, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, enzymes, anti-parkinson agents, gastro-intestinal agents,
histamine receptor antagonists, lipid regulating agents, local anaesthetics, neuromuscular agents, nitrates and anti-anginal agents, opioid analgesics, proteins, peptides, recombinant drugs, sex hormones, contraceptives, spermicides, stimulants etc.

A process for the preparation of ODT's (in this specification also denoted as "disintegrating tablets") is known i.a. from US 5,384,124 assigned to Farmalyoc. In the known process a paste comprising one or more medicinal substances is formed, which paste is mechanically divided into unitary doses having a well defined shape and volume, by distributing the paste in cavities of predetermined shape and size, which cavities are present in a polyvinyl chloride carrier element. After distributing the paste, the carrier element is put in a lyophiliser and the paste is freeze-dried. This way, each unitary dose is formed into a tablet. The advantage of the freeze-drying process is not only that the medicinal substance is brought in a very stable form, but also that a solid dosage form is obtained that disintegrates upon contact with a liquid. In particularly, if the paste originally was based on water as the carrying solvent (the term "solvent" includes any liquid medium may serve as a carrier for other substances), such a tablet will normally disintegrate upon contact with water or a water based fluid such as saliva.

The known method is being widely used in the life-sciences industry (see for example "Orally disintegrating tablets: an overview of melt-mouth tablet technologies and techniques" by Deepak Kaushik, Harish Dureja and T.R. Saini, Maharishi Dayanand University and Shri G.S. Institute of Technology and Science, as published in "Tablets and Capsules", 30 July 2004). In particular technologies such as Zydis (Catalent Pharma Solutions, Somerset, NJ, USA) and Lyoc (Laboratoires Farmalyoc, Maisons-Alfort, France) use this known process. Typically the starting paste or fluid formulation is prepared and dosed into a preformed blister pack. This pack, i.e. the material present in the pack, is then frozen and subjected to freeze-drying to remove water. The resultant structures are inherently very porous and rapidly disintegrate when they contact saliva. Indeed, this method is very advantageous in that tablets can be made that very rapidly disintegrate, show adequate pharmacokinetic characteristics, better patient compliance and higher bioavailability when compared with reference oral solid formulations, and side-effect reduction (see "Fast-Melting Tablets: Developments and Technologies" by Luca Dobetti, in Pharmaceutical Technology Drug Delivery, 2001, pp 44-50). Known disadvantages are that the tablets have a relatively poor mechanical stability and high cost of production. These disadvantages however are believed to be inherent due to the
freeze-dry process used: Freeze-drying needs expensive equipment and inherently leads to mechanically less stable tablets when compared e.g. to traditional compression techniques. Due to this fact the known process takes place by using the final tablet package (i.e. the blister package) as a carrier throughout the complete process. This inherently means that each production step has to be adjusted such that it can be used in conjunction with this particular package. This limits the freedom of operation in the various manufacturing steps and thus increases cost price even further. However, given the advantages of freeze-dried products as disintegrating tablets, the inherent high cost price of the manufacturing process is accepted by the manufacturing practitioner.

It is noted that other methods to arrive at ODT's are known from the prior art. For example, WO 93/12770 and US 2006/0057207 (both assigned to Pfizer Inc.) describe a method wherein the tablets are actively shaped over substantially their entire surface by compressing the frozen pellets in a closed mould. This known method thus defers from passively obtaining a tablet shape, for example by using a passively arrived shape that occurs through the mere action of gravity and surface tension. This way a predetermined shape can be arrived at easily in a controlled manner. This method is disadvantageous however in that it requires a rather complex die-and-punch assembly that is prone to leakage of the fluid formulation from the cavity (i.e. the closed mould). Also, frozen pellets tend to stick to either the die or punch due to the use of compression forces. An advantage indeed is that by compressing the frozen pellet, good mechanical properties are obtained which allow the frozen pellet to be taken out of the cavity integrally.

From US 5,382,437 and EP 0 450 141 yet another method is known wherein the fluid formulation is brought over into open cavities of a solid element which is at room temperature, whereafter this element is brought over in a freezer for 30-60 minutes. This appears to be advantageous since the fluid formulation namely will nicely fill the cavity, thus leading to a frozen pellet of a size and shape that exactly corresponds to the size and shape of the cavity, and thus leading to a predictable pellet form. Disadvantages however are that a cooling-heating cycle has to take place with this method and also that the entire process is relatively slow. Also, there is a risk of loosing fluid from the cavity upon filling them with the (low viscosity) fluid formulation.

SUMMARY OF THE INVENTION
It is an object of the present invention to arrive at a process for obtaining an orally
disintegrating tablet for administration to a human subject, using freeze-drying as a
basic technology, which has a significantly reduced cost price per tablet, while at the
same time having excellent disintegration properties and adequate mechanical stability.
To this end a process according to the preamble has been devised comprising the steps
of providing a fluid formulation comprising the medicinal substance, providing a solid
element having formed therein at least one cavity, cooling the solid element to a
temperature below a freezing temperature of the formulation, filling the cavity with the
fluid formulation, solidifying the formulation while present in the cavity by extracting heat
from the formulation through a cavity wall by conduction, to form a solid pellet
comprising the medicinal substance without actively shaping the entire surface of the
pellet, taking the pellet out of the cavity, and drying the pellet in a vacuum to obtain the
tablet.

Applicant surprisingly found that adequate disintegrating and mechanical properties of
an ODT can be arrived at, while at the same time significantly increasing the freedom in
the manufacturing process, and thus opening possibilities for significantly decreasing
the cost price per tablet, by firstly filling an open cavity with a fluid formulation
comprising the medicinal substance (which also covers filling the cavity with two or more
separate sub-formulations which together form the fluid formulation containing the
medicinal substance) and then freezing the fluid formulation in that cavity to form a solid
pellet by simply leaving the fluid formulation in the pre-cooled cavity, not applying any
active shaping tools such that one may end up with an uncompressed frozen pellet
having a shape (at the open end of the cavity) that is formed merely by gravitational
forces and surface tension (a meniscus), taking the frozen pellet out of the cavity, and
after that drying the pellet (for example in a lyophilising apparatus). It was also found
that it is particularly advantageous to have the solid element at a temperature below the
freezing temperature of the formulation upon filling the cavity. At first glance this seems
a disadvantage: The fluid formulation namely will start to solidify immediately upon
contact with the cavity wall, theoretically leading to a frozen pellet of a size and shape
that does not correspond to the size and shape of the cavity, thus leading to an
uncontrolled freezing process and thus an unpredictable pellet form. However, applicant
found that for a temperature below the freezing temperature of the fluid formulation a
filling speed can be found that is fast enough to counterbalance the immediate freezing
of the fluid, simply because the amount of heat present in the flow of fluid formulation
may simply counterbalance the extraction of heat by the cold solid element, or at least
an adequate part of the heat extraction. Overall, the new process is easier to control: the temperature of the solid element can be kept at the same level, whereas a cooling-heating cycle has to take place with prior art methods. Moreover, the process is faster. Heat is already being extracted upon filling the cavity. Also, there is less risk of losing fluid from the cavity, since the fluid will cool down very fast after entry of the cavity and thus will immediately show an increased viscosity.

The new process has several important advantages with regard to the most pertinent prior art as known from Farmalyoc. Firstly, in this new process the final tablet package does not need to be involved in any of the process steps. Therefore, not only a standard cheap package may be used, but also, each of the manufacturing steps can take place with tools optimised for their task. With the prior art process for example, where a blister package is used as the carrier for the tablets in a lyophiliser, the drying circumstances have to be adjusted to the relatively low amount of heat that can be transferred through the (plastic) package. This may significantly increase the thermal load (for example a high local temperature) on each tablet during the drying step and also may significantly increase the necessary process time. Applicant also found that extracting heat from the formulation through a cavity wall by conduction (meaning that at least the main part, i.e. more than 50%, preferably more than 80% up to 100% of the heat that is to be extracted to freeze the formulation, is extracted by conduction through the cavity wall) has a significant positive impact. This not only overcomes or at least mitigates the prior art problem of thermal load on the pellet, but also may improve the mechanical strength of the final ODT. In the known processes nearly all of the heat is extracted by convection, in particular using nitrogen gas that travels around the fluid formulation to extract heat until the formulation is solidified and has transformed into a frozen pellet. Although convection can be adequately used to freeze the fluid formulation, applicant found that when conduction is used, by having a heat conducting material around at least part of the fluid formulation, the cooling process may provide a pellet with advantageous mechanical stability, for example an adequate mechanical strength and/or low friability, while maintaining its fast disintegrating properties at a high level. The reason for this is not clear but may be due to the fact that extraction of heat by conduction provides a more efficient and thus significantly faster cooling process, which leads to a different arrangement of the constituting molecules in the pellet. It is noted that in the prior art methods, a small amount of heat may be extracted from the fluid formulation through the wall of the blister. This however does not qualify as heat extraction by conduction in the sense of the present invention since the blister package material is a plastic, which
typically has a heat transfer coefficient of 0.1 to 0.2 W/mK, which inevitably means that
the main part of the heat is extracted by other means than conduction (viz. convection
through the flow of cold nitrogen gas).

Another major advantage of the present method is that the tablets in the finished packed
product are not present in the mould in which they have been formed. With the prior art
methods, the pellets are formed in the blister package which serves as a mould. The
pellets however stay in their moulds during the complete process, until they are
transformed into tablets present in their finished packaging. Therefore there is a high
risk that the tablets more or less stick to the blister wall and can only be removed by
applying considerable mechanical forces. This, in combination with the fact that freeze-
dried tablets are inherently not too stable (when compared to classic compressed
tablets) often results in tablets being broken even before they can be administered. This
may lead to tablets not being used or too little active ingredient being administered to a
patient.

Another important advantage of the present process is that the freezing step does not
need to take place in the lyophiliser itself. In the process known from US 5,384,124 the
freezing step takes place in the lyophiliser since the paste is present in the blister
package anyway. However, in the known process, extracting heat from the paste to
freeze it takes a relatively long time. In the present method, by solidifying the fluid
formulation in a separate step in a dedicated cavity, and thereafter taking the frozen
pellet out of the cavity and subject it to a lyophilising action in an additional step, the
initial freezing can be done significantly more efficiently.

Yet another substantial advantage of the present invention is that the step of obtaining
the solid frozen pellets does not depend on the available drying capacity. Since the
provision of the frozen pellets is completely independent of the drying step, the pellets
can be produced separately and for example stored until drying capacity comes
available. In particular when the medicinal substance is of biological origin, it is
important that a batch of fluid formulation containing this substance can be completely
processed into frozen pellets, independently from the currently available drying capacity.

Also, with the present invention it is possible to produce tablets with (almost) spherical,
oblate, "egg"-like or oval shapes in three dimensions without any flat face. As is known,
shapes that approach the spherical shape are inherently mechanically strong, while the
shape does not significantly affect the fast disintegrating properties of the units.

With regard to the die-and-punch methods as known from the prior art, the present
method has the important advantage that it does not suffer from leakage of the fluid
formulation from the cavity. Since the fluid formulation is simply left to freeze in the open cavity without actively shaping the entire surface of the pellet by applying e.g. compression forces or other active moulding techniques that shape the surface of the pellet, there is no risk of fluid formulation being pressed out of the cavity. Also, there is a significantly decreased risk of the pellet sticking to any of the parts used for actively shaping the pellet. Surprisingly it appeared that by simply leaving the fluid formulation to freeze, without applying any compression forces, the pellet still may have sufficient mechanical strength to be taken out of the cavity for further processing such as lyophilising.

It is noted that the present invention can be used in conjunction with any medicinal substance and/or combinations thereof. Typical examples of such substances can be found in EP 1 165 053 B1, starting on page 5, line 37 (starting with "Analgesics and anti-inflammatory agents:" and ending on page 7, line 25 (ending with "...fenfluramine, mazindol, pemoline.") Other examples are progestogen-type compounds (such as desogestrel, etonogestrel, levonorgestrel, norgestimate, norelgestromin, gestodene, nomegestrol acetate, dienogest, drospirenone, or any other steroidal or non-steroidal compound with progestogenic activity), estrogen-type compounds (such as such as estradiol, estriol, mestranol, ethinyl-estradiol or any other steroidal or non-steroidal compound with estrogenic activity), and compounds in the field of the central nervous system (such as asenapine, mirtazapine, esmirtazapine or other compounds with CNS activity).

The present invention is based on several recognitions, the first one being that the finished freeze-dried product may be mechanically not too stable, but the intermediate frozen product surprisingly does not suffer from this disadvantage despite the fact that this frozen product is not compressed. This opens possibilities for additional mechanical handling of the intermediate pellet. However, such handling in the known Farmalyoc process makes no sense, since the frozen pellet is already present in the lyophiliser in its final blister package. Applicant however came to a second insight, namely that the drying step in this known method is very inefficient mainly due to the fact that when using the final tablet package as a carrier in the lyophiliser, the drying space is not adequately used (each tablet takes a relatively large amount of space since the tablets cannot be in a contiguous relation in the package). This inefficient use of the lyophiliser in the known process is inherent, but can be overcome by separating the freezing and drying step by using a carrier for the freezing step that differs from the carrier used in
the drying step. A third insight was that in the known process, due to the relatively slow freezing step, the original liquid formulation is frozen almost under equilibrium conditions. This typically leads to the commonly known very brittle end products when dried. Applicant recognized that a significantly faster cooling process may lead to a solidification process that provides a more amorphous-like end-product, leading to a less vulnerable end-product. This may show as a higher crushing strength of the tablets or a lower friability (as defined in the U.S. Pharmacopeia 24/NF19, 1999, p. 2148-2149).

It is noted that the present invention also pertains to an orally disintegrating tablet for administration to a human subject wherein the tablet has a curved surface, preferably having a relative curvature $K$ of between 1 and 1.2. An important advantage of the process according to the invention is that it may lead to tablets with a high mechanical strength when compared to tablets made according to existing technologies. This mitigates prior art disadvantages, such as the necessity of individually packing each tablet in a peel-off blister package. With the current invention, tablets can be made that are bulk-packed or packed in regular push-through blister packages.

The present invention also concerns a package containing an orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a disorder of the human subject, wherein the tablet preferably but not necessarily is individually packed in a container and is formed in a cavity using a method according to the present invention, the cavity being different from the container in which the tablet is packed (e.g. a blister of a blister package). As described hereabove, a major advantage of the present invention is that tablets in the finished packed product are not present in the mould in which they have been formed, which almost excludes the chance of a tablet sticking to its container, e.g. a blister of a blister package, in the finished package. This near exclusion improves the convenience of handling the tablets by a physician, DVM, patient or the like.

DEFINITIONS

A tablet is a solid dosage form, for example for direct oral, rectal or parenteral administration or for indirect administration for example after mixture with a carrier material, in particular a liquid, for administration in a dissolved or dispersed form. A tablet can be distinguished from powder or fine granules in that a tablet can be
individually manually handled. A minimum length size of a tablet is 1 mm, preferably 2 mm, more preferably 4 mm and typically (but not necessarily) between 4 and 20 mm.

An orally disintegrating tablet is a freeze-dried tablet that disintegrates upon contact with saliva, for example in the oral cavity, within 60 seconds, preferably within 30 seconds, more preferably within 10 seconds.

Freeze-drying or lyophilisation is a process used in the creation of a stable preparation of a substance by freezing a fluid formulation containing the substance and substantially remove the frozen liquid under vacuum.

A vacuum is air or other gas at a reduced (sub-atmospheric) pressure.

To disintegrate is to lose unity and be reduced to fragments. The term “disintegrate” covers dissolution (having fragments at molecular level).

Fast-disintegration means disintegration which starts upon contact with a liquid, in particular water at 37°C, and is completed within 60 seconds, preferably within 30 seconds, more preferably within 10 seconds.

A medicinal substance is any substance that can be used to treat a disorder (including diseases), i.e. to aid in preventing, ameliorating or curing the disorder. Such a substance may for example be a chemical or biological compound, such as a natural or synthetic peptide or protein, a (poly-)saccharide or any other organic or inorganic molecule, a dead or alive micro-organism, a dead or alive parasite etc.

A freezing temperature of a fluid formulation is a temperature at which the consistency of the formulation transforms from liquid to solid, i.e. a consistency which can withstand an external force without a change of form.

A heat conducting material is a material having a heat transfer coefficient of at least 1 W/mK (Watt per meter Kelvin).

Abhesive means the capability of resisting adhesion.

A crystalline material is a material that can form crystals upon solidification under
equilibrium conditions.

A gelator is an agent that is capable of forming a network of molecules within a fluid to provide the fluid the consistency of a gel, i.e. having at least some self-supporting capacity (not being a free-flowing liquid under all circumstances). The term gelator also covers an agent comprising two or more different compounds or materials that each are capable of forming a network of molecules within a fluid.

A gel-forming material is a material that at a concentration of 4% (w/w) in a fluid formulation, in particular water, at a temperature at which that fluid formulation is used for dosing purposes (in the present case for filling cavities at room temperature, 20°C), forms a gel in the said fluid formulation when left in a stationary situation for 24 hours.

A non gel-forming material is a material that at a concentration of 4% (w/w) in a fluid formulation, in particular water, at a temperature at which that fluid formulation is used for dosing purposes (in the present case for filling cavities at room temperature, 20°C), does not form a gel in the said fluid formulation when left in a stationary situation for 24 hours.

EMBODIMENTS OF THE INVENTION

An ODT ideally meets multiple demands, for example sufficient mechanical strength for manual handling (to enable easy removal of a tablet from a package and allow putting the tablet in the mouth of a patient), optionally possess mucoadhesive properties (for example such that a tablet will disintegrate in the mouth and not reach the stomach), while not being sticky in order not to hamper handling of the tablet, having an acceptable taste, and providing a very rapid disintegration (such that for example high blood levels of the medicinal substance can be obtained). The liquid formulation used for making the tablets may optionally contain additives such as for example surfactants or other substances which can be used to give the final tablet properties useful for the specific use of the tablet. Such substances may for example be colorants, sweeteners or other taste modifying or masking agents, preservatives, chelates, anti-oxidants, surfactants, colouring agents, pH modifiers or any other substance that is compatible with the rest of the constituents of the tablet, and if necessary pharmaceutically acceptable for the intended patient.
In an embodiment of the present the volume of the cavity is smaller than the volume of
the pellet. In the prior art methods, a cavity (or mold) is chosen that exactly corresponds
to the size and shape of the tablet to be formed. Surprisingly however, applicant found
that a cavity may be used that has a volume smaller than that of the tablet to be formed.
In this embodiment the pellet projects from the surface of the element, out of the cavity.
This is enabled i.a. since the fluid formulation is rapidly cooled by the conductive contact
with the cold element. This helps to ensure that a pellet can be formed that even sticks
out of the cavity. An advantage of this particular embodiment is that the pellet can be
removed relatively easy from the cavity since the contact surface between the pellet and
cavity is small when compared to a pellet that is completely enclosed by or sunk in the
cavity. Another advantage of this embodiment is that there may be provided a
discontinuity in the physical appearance of the tablet corresponding to the transition site
between the cavity and the open space above the cavity. Since the pellet to be formed
sticks out of the cavity, there may be provided such a discontinuity in the shape of the
pellet at the cavity entry. Such a discontinuity may be used to distinguish the tablet from
other tablets (thus being for example an alternative for a company logo, icon or colour),
or may be used to provide advantageous mechanical properties.
In a preferred embodiment, the volume of the cavity is smaller than 50% of the volume
of the pellet. In this embodiment, more than half of the pellet sticks out of the element in
which the cavity is formed. This makes removal of the pellet very easy. A minimum
volume to ensure a practically adequate heat extraction from the fluid formulation is
about 15%, preferably about 20%.

In a particular embodiment of the process according to the invention the formulation
comprises a crystalline carrier material that is solid at room temperature and a gelator. A
crystalline carrier has the advantage that it can be easy formulated into a fluid
formulation, and that it provides good mechanical properties to the tablet. The gelator is
incorporated to even further improve the mechanical properties of the tablet. Examples
of suitable carrier materials are sugars such as mannitol, dextrose, lactose, galactose,
trehalose and cyclic sugars such as cyclodextrin, inorganic salts such as sodium
phosphate, sodium chloride and aluminium silicates, amino acids typically having from 2
to 12 carbon atoms such as glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-
hydroxyproline, L-isoleucine, L-leucine and L-phenylalanine. The gelator may be any
agent that is capable of forming a network of molecules within a fluid to provide the fluid
the consistency of a gel. Such an agent may comprise high molecular proteins or other
polymers but may also be based on small molecules that can form networks through recombination of the small molecules into long chains (as known i.a. from US 6,471,758). The gelator has the advantage that the large molecules provide additional mechanical stability to the final tablet. Typical examples of gelators are gelatins, dextrins and soy-, wheat- and psyllium seed proteins, gums such as guar, agar, acacia, xanthan and carreagenan, polysachharides, alginates, carboxymethylcelluloses, pectins, polyvinylpyrrolidone etc.

In a further embodiment the formulation comprises 3 or more weight percent of the crystalline material and about 4 weight percent of the gelator. Typically the amount of a crystalline carrier material in a formulation to obtain an ODT is kept below 3 weight percent. For the gelator preferably an amount of about 4 weight percent is used. Applicant found that when using 3 or more weight percent of the crystalline carrier and at the same time using about 4 weight percent of the gelator, surprisingly this may lead to a high mechanical strength of the final tablet and very good disintegration properties.

In an embodiment the gelator comprises a non gel-forming material, preferably a collagen derived material, such as a gelatine. Although the gelator in principle is capable of forming a gel in a liquid, we found that it is advantageous to choose a gelator that not, or at least not completely, forms a gel in the liquid formulation when filling the cavity (this can be simply accomplished by choosing a gelling compound or material that dissolves in the fluid formulation at the said temperature in stead of forming a network of gelator molecules in the fluid). This simplifies the dosing of the fluid formulation, given the less high viscosity and/or the less non-Newtonian behaviour of the fluid formulation.

After dosing, upon lowering the temperature the gelator will form a gel. In a preferred embodiment the collagen derived material is a gelatin having a weight average molecular weight of $2 \times 10^4$ g/mol (thus having an actual average weight between 15,000 and 25,000 g/mol). Applicant found that the use of such a gelator may lead to less sticky tablets, and also, to tablets having very good disintegration properties while keeping adequate mechanical strength despite the relatively low molecular weight of the gelator. Gelati Sol P (available from Gelita, Eberbach Germany) is a good example of such a gelator. It is noted that gelator strength is traditionally referred to as Bloom. It is the force, expressed in grams, necessary to depress by 4 mm the surface of a gel with a standard plunger having a diameter of 0.5 inch. For gelatines, the gelator is used at a concentration of 6.67% and the gel should be kept at $10^0\text{C}$ for 17 hours before testing. Bloom is linked to mechanical elasticity of the gel and is i.a. used to classify gelatine
types. It generally ranges from 10 to 300 Bloom. Gelati Sol P has a bloom strength of about 15-25.

In yet another embodiment, the volume of the pellet is larger than a maximum volume of a free droplet of the fluid formulation at a temperature and pressure used when filling the cavity. In this embodiment the pellet is bigger than a single free droplet of the fluid formulation. This embodiment is advantageous in obtaining tablets of a size that can be easily handled manually, based on a fluid formulation of which one single free droplet would only be as large as for example 50 µl. For example, if the fluid formulation is based on water as a solvent (carrier fluid) than a single free droplet at a temperature of 20°C and a pressure of 1 atmosphere is about 50 µl. After freezing and drying such a droplet, the diameter will be about 2.3 mm. This is quite small for manual handling. It is preferred that larger tablets are made. In the prior art, this is accomplished by transforming the fluid formulation into a formulation such that droplets up to 1 ml can be obtained. For this however, all kinds of additives are required to give the fluid formulation a gel-like consistency. These additives not only make the production process more complex, they must also be taken into account when assessing compatibility with the subject patient. Although freezing one single droplet has advantages process wise, it was applicants merit to find out that constituting a pellet out of a volume that correspond to the volume of multiple single droplets, leads to less stringent conditions for the constituents of the fluid formulation, simply because less compounds need to be present in the formulation.

In a further embodiment, the speed at which the cavity is filled with the fluid formulation is chosen such that the surface of the part of the pellet that is in the cavity before the pellet is taken out of this cavity, is in essence a negative print of the surface of the cavity. It was found that a filling speed can be chosen such that the surface of the pellet, at least the part that is contiguous to the cavity, is in essence a negative print of the surface of the cavity (in essence meaning at least as far as visible with the naked human eye). When the filling speed is below this speed, an uneven pellet surface will be formed since the fluid that enters the cavity will solidify before it can completely wet the surface of the cavity. Complete wetting is found particularly suitable not only to form nice and smooth pellets and thus tablets, but also, this gives the opportunity to form a logo or any other identifying means in the tablet (for example a logo of the commercial
party bringing the tablet to the market or any other imprint). For this, one needs to have a mirror image of the imprint in the cavity wall (either positive, that is being applied on top of the wall, or negative, that is being indented in the wall).

A cross-section of the part of the pellet that is in the cavity may be smaller than a cross-section of the cavity at its entrance. In this embodiment the pellet can be easily removed from the cavity, for example by simply pushing or pulling the pellet out the cavity, using a mechanical force, air pressure, gravity etc.

In an embodiment, a measure is taken to support automatic detachment of the pellet from the cavity wall. Automatic detachment, i.e. without mechanical intervention of any kind, significantly reduces the chances that a pellet will be damaged upon removal from its corresponding cavity. In an embodiment wherein the cavity is formed in a solid element, the automatic detachment is supported by keeping the temperature of the solid element adequately beneath the freezing temperature of the fluid formulation. It has been found that for every fluid formulation, a temperature can be found which is that low, that it generates a speed of shrinkage of the pellet sufficient to induce automatic detachment of the pellet from the cavity wall. For a water based fluid formulation, the temperature should be at least 80 degrees (K) below the freezing point of the formulation, thus about -80°C. Preferably the difference is about 100-120 degrees up to even 196 degrees. The difference needed depends on the constitution of the formulation but can simply be found by increasing it from 0, until automatic detachment is provided. Such detachment can be recognised easily since upon automatic detachment, the pellet can be simply removed from the cavity using merely gravitational forces (turning the element upside down). In another embodiment the automatic detachment is supported by providing the cavity wall with an abhesive surface by chemical and/or physical means. Commonly known chemical means for obtaining an abhesive surface are for example coatings with a high fluorine content (Teflon® for example) or high silicone content. Physical means are for example lotus leaf-like structures or commonly known nanopins. An abhesive surface has the additional advantage that the pellet can be formed in a very shallow cavity. However, a disadvantage is that complete wetting of the surface to form a negative print of the cavity wall is inherently difficult to achieve.

The pellet may be taken out of the cavity by applying a pushing force to the pellet. It has been found that applying a pushing force, despite inherent risk of mechanically
damaging the frozen pellet, provides excellent results with regard to removing a pellet from the cavity while keeping its shape intact. The advantage of a pushing force over for example a stream of blowing gas is that pushing can be done with a clean mechanical element, while a stream of air has inherent sterility problems. In a preferred embodiment the pellet is pushed out of the cavity using a tangentially directed force. It was found that a tangential force, although less direct, has the advantage that there is less mechanical impact on the pellet, while even improving the removal process. By applying a tangential force, the pellet can start to twist and turn in its cavity which will lead to easy and reliable removal without damaging the pellet.

Multiple pellets may be placed in a packed bed before the pellets are dried in the vacuum. In this embodiment the pellets are not dried while arranged in a single layer, but are packed to be part of a multiple layer bed. This way the drying step, which may take place in a lyophiliser, is operated at a significantly higher efficiency. However, since the drying process depends inter alia on heat transfer through the bed, the number of layers will be restricted to 2 or 3. In a further embodiment therefore, the pellets are arranged in a heat conducting container having a bottom and side walls, and a heat source is provided above a top layer of the packed pellets, the heat source having a surface directed to a top layer of the bed, which surface has an emissivity coefficient of at least 0.4, whereafter the pellets are subjected to the vacuum while at the same time heating at least the bottom of the container and the said surface to provide heat to the particles to support drying of the pellets. In this embodiment the number of layers in the bed can be increased to be over 3. However, also when applying a mono-layer of pellets, the additional heat source can be advantageously used, for example for providing a faster drying process, but more preferably for providing a better drying result. The emissivity coefficient (usually denoted as $\varepsilon$) in this respect is the ratio of energy radiated by the surface to energy radiated by a true black body of the same temperature. It is a measure of the ability to absorb and radiate energy. A true black body would have an $\varepsilon = 1$ while any real surface or object would have an $\varepsilon < 1$.

Emissivity is a numerical value and does not have units. By having an emissivity coefficient of at least 0.4, the heated surface radiates relatively high quantities of heat to the particles. Emissivity in the sense of the present invention is the mean emissivity as established at four different temperatures of the surface, viz. 55, 60, 65 and 70°C. The emissivity can be measured by using dedicated emissivity measurement equipment as commercially available such as the Model 205WB of Advanced Fuel Research Inc., East Hartford, CT USA. Such equipment however is very expensive. Alternatively, as
commonly known, a very simple way of measuring the emissivity is to heat the surface and a surface with a known emissivity to the same temperature as determined by a thermocouple. Then read the temperature of the two surfaces with a standard infrared pyrometer. The difference in the two infrared temperature measurements is due to the difference in the emissivities of the surfaces (see also Applied Optics, Vol. 13, No 9, September 1974).

As far as the final tablet is concerned, in an embodiment the tablet comprises a crystalline carrier material that is solid at room temperature and a gelator as described here-above. Also, the tablet may be formed out of a fluid formulation comprising 3 or more weight percent of the crystalline material and about 4 weight percent of the gelator. Preferably, the tablet comprises a gelator comprising at least 2 weight percent of a gel-forming material, for example (preferably) a collagen derived material such as gelatine. It is further preferred to add a non gel-forming material, for example (preferably) a collagen derived material such as gelatine, to improve disintegration properties. This non gel-forming gelatine can be a gelatine having a weight average molecular weight of $2 \times 10^4$ g/mol.

**SPECIFIC EXAMPLES OF THE INVENTION**

The invention will now be explained in more detail used the following non-limiting examples

Figure 1 schematically shows a cavity tray and corresponding cooling element for use in a method to obtain frozen pellets

Figure 2 schematically shows the basic parts of an apparatus for obtaining frozen pellets

Figure 3 is a schematic top plan view of some parts of the apparatus as depicted in figure 2

Figure 4 schematically depicts a filling needle in conjunction with the corresponding cavity

Figure 5 schematically shows a drying chamber for use in the present method and system.

Figure 6 schematically shows a tensile tester for establishing the crushing strength of a tablet.
Figure 7 schematically shows a package containing a tablet according to the invention.
Figure 8 schematically shows a device to measure the stability of tablets when being pressed through a foil.
Figure 9 schematically shows examples of tablets being pressed through a foil.

Example 1 Obtaining ODT's with a live vaccine component
Example 2 Obtaining ODT's with a chemical drug
Example 3 Establishing the mechanical stability of an ODT
Example 4 Alternative way of establishing the mechanical stability of an ODT

**Figure 1**

Figure 1A schematically shows a cavity tray 100 and corresponding cooling element 105 for use in a method to obtain frozen pellets. Cavity tray 100 is a solid steel plate (made of stainless steel, grade 316L) having a thickness of 6 mm. In the plate three rows (102, 103 and 104) of cavities 101 are formed. Figure 1B gives an example of a first type of cavity. The shown cavity 101 has a spherical shape, a radius r of 2.9 mm and a depth d of 2.1 mm. In such a cavity, a spherical pellet 30 with a volume of about 100 µl (having a radius of about 2.9 mm) can be formed. Another example, which can be used for larger tablets, is shown in figure 1B. This cavity 101' is also spherical, has a radius r of 4.9 mm and a depth of 4.0 mm. In such a cavity a spherical pellet 30' with a volume of about 500 µl (having a radius of about 4.9 mm) can be formed. Indeed, other sizes (for example between 50µl and 1000 µl) and shapes can also be provided for, for example to obtain an oblate (also known as "M&M"- or "Smartie"-shaped) pellet, an egg-shaped pellet, an oval (zeppelin-shaped) pellet etc. In particular, an oblate pellet can be formed in an oblate cavity having a length and width of 6.0 mm and a depth of 3.3 mm by dosing a volume of about 300 µl.

Tray 100 rests under gravitational forces on cooling element 105 (in an alternative embodiment, the tray can be clamped to cooling element 105). This element is a hollow stainless steel box, having a height of about 6 cm. The box 105 has an entrance 106 and an outlet 107. Through the entrance 106, liquid nitrogen can be supplied (indicated by the arrow A) at a temperature of about -196°C. At the outlet 107 nitrogen (a mixture of liquid and gas) leaves the box 105 (indicated by the arrow B). This way the tray 100
can be cooled adequately to obtain a very fast solidification process when a fluid formulation is dispensed in one (or more) of the cavities 101. Depending i.a. on the temperature of the fluid formulation, the temperature of the surrounding air, the nitrogen flow and the speed at which solid pellets are produced, an equilibrium temperature of between -85°C and -145°C for the tray 100 can be obtained in the shown arrangement.

**Figure 2**

Figure 2 schematically shows the basic parts of an apparatus for obtaining frozen pellets. The same tray 100 and cooling element 105 as depicted in figure 1 can be seen. At the front (downstream of the tray 100) a black plastic container 15 is shown, which container has handles 16 for manually handling the container. This container 15 is placed directly against cooling element 105. The container is cooled to a temperature of about -45°C by having its support (not shown) cooled by using liquid nitrogen. At the other side of the tray 100 (upstream side) a collecting element 120 is shown, which element is divided into three compartments 121, 122 and 123. This element travels over the surface of tray 100 (with a space of about 0.2 mm between the bottom of element 120 and the surface of tray 100) in the direction C and pushes frozen pellets out of their cavities. These pellets are then collected in each of the compartments 121, 122 and 123 and are ultimately brought over into container 15. Attached to collecting element 120, via brackets 131, is dispensing unit 130. This unit comprises three needles 132, 133 and 134, corresponding to cavity rows 102, 103 and 104 respectively. The needles are used to dispense the fluid formulation in each of the cavities. The fluid formulation is supplied to each of the needles via tubes 152, 153 and 154 respectively.

When operating the device, the atmosphere is cooled to a temperature of around 15°C using dry nitrogen gas. Because of this relatively high temperature of the surrounding atmosphere, a water based fluid formulation can be handled in and around the apparatus without the risk that the formulation freezes in the tubes 152, 153, 154 or the needles 132, 133 and 134. Dry nitrogen gas is used to prevent crystallization of water into ice on the various parts that are kept below 0°C. In this setup, the tray 100 will have an equilibrium temperature of about -125°C. The collecting element 120 has a temperature around -35°C, and the container 15 will have a temperature of about -45°C.

The process starts with moving the element 120 in the direction C until the needles coincide with the first (upstream) cavities. Then the movement of element 120 is
temporarily stopped, and the first three cavities are filled with fluid formulation. When finished, the element 120 moves forward until the needles coincide with the next three cavities. Then, these cavities are filled with fluid formulation. This process continues till all cavities are filled with the fluid formulation. Then the element 120 is lifted somewhat (about 25 mm) and brought back to its original position at the upstream part of the tray 100. Then the element 120 travels forward again in the shown direction C. This time, the element will come across frozen pellets in each of the cavities. The pellets are pushed out of their cavities and collecting in the compartments 121, 122 and 123 respectively. In this process, each pellet may remain between 20 and 90 seconds in its cavity (from filling until pushing out, depending i.a. on the size of the pellet: the larger the pellet, the longer the solidification process will take). At the same time, upstream of element 120, the emptied cavities are refilled as described here-above. This process continues until container 15 is adequately filled with frozen pellets.

Figure 3
Figure 3 is a schematic top plan view of parts of the apparatus as depicted in figure 2. In this schematic view, the inner arrangement of collecting element 120 is shown. Each compartment 121, 122 and 123 comprises an inner slanted wall 141, 142 and 143 respectively. Each of these walls is slanted with respect to moving direction C with an angle of 10°. The walls hit the frozen pellets and push them out of their cavities. Since each wall is slanted, the pellets are pushed out with a tangentially directed force. This has the advantage that the pellets are more or less twisted out of their cavities. It has appeared that this significantly reduces the risk of pellets being damaged. When they are pushed out, the pellets are collected at the back of the compartments, in this case in roundings 161, 162 and 163 respectively. At the downstream position of the element 120 (adjacent container 15) the pellets will automatically fall into container 15.

Figure 4
Figure 4 schematically depicts a filling needle in conjunction with the corresponding cavity. The needle 132 has a tip 232. This tip 232 is arranged to have a vertical position with respect to the surface of tray 100, such that the tip coincides with the uppermost part of the pellet 30 to be formed in cavity 101. From this position, the cavity is filled with fluid formulation. The speed of filling can be tuned to obtain any desired filling process. For example, when a very low speed is chosen, a rather irregular shaped pellet will be
formed, i.a. since the fluid will not be able to completely wet the cavity wall. When a sufficiently high speed is chosen a complete wetting can be achieved. This speed depends i.a. on the actual temperature of the fluid at the time of filling the cavity, the cavity wall temperature, the viscosity of the fluid etc. For each formulation this speed can be found by performing routine experiments. After the required amount of fluid formulation is filled, the needle travels further to the next cavity. However, it is preferred that a waiting time, for example about 0.1 seconds, is used between the moment when all formulation has been dispensed and the moment at which the needle starts traveling again. This may prevent mechanically disturbing the dosed pellet. It is noted that in this particular example a spherical pellet 30 is depicted. However, other shapes can also be formed. In any case, the optimal position for the tip is right at the uppermost part of the pellet to be formed.

**Figure 5**

In figure 5 a lyophiliser (freeze-dry apparatus) is schematically depicted. Such a lyophiliser could for example be the Christ Epsilon 2-12D as available from Salm en Kipp, Breukelen, The Netherlands. The lyophiliser 1 comprises a housing 2 and multiple shelves 3. The Epsilon 2-12D comprises 4 + 1 shelves, for matters of convenience three of these shelves (viz. shelves 3a, 3b and 3c) are shown in figure 1. Each of these shelves is provided with a heating element 5 (referred to with numerals 5a, 5b and 5c respectively) for even heating of the shelves 3. The heating is controlled by making use of processing unit 10. The housing is connected to a pump unit 11 for providing adequate low pressure within the housing 2. The interior of the housing can be cooled to a temperature as low as -60°C by using cooling unit 12, in particular containing a condenser (in fact, it is the condenser that is kept at about -60°C, which acts as a driving force for condensation of sublimated ice). Shelves 3a and 3b are provided with black PTFE plates 8 and 8' fixed to their bottom. The emissivity coefficient of these plates is 0.78. By intimate contact between these black plates and the shelves, these plates can be warmed virtually to the same temperature as the shelves themselves. This way, the plates 8 can be regarded as heat source in addition to the shelves 3 themselves.

Placed on the shelves are container 15 and 15'. These containers are made of a heat conducting material, in this case carbon black filled polyethyleneterephtalate. The containers are in a heat conducting contact with the shelves on which they rest. In the
shown arrangement, the containers are filled with frozen pellets 30 which thus form a bed 29 of packed pellets in each container. By heating the shelves, the particles may receive heat via the heated bottom and side walls of the containers and by irradiation from the heated plates 8 and 8' respectively. It is noted that each container 15 has a width and length of about 20 to 30 cm and a height of about 4 cm. The height of the packed bed after filling the container is typically 1.5 to 3 cm. This leads to typical values for an aspect ratio of the bed of between 20/3 \approx 7 to about 30/1.5 \approx 20. However, monolayer arrangement of pellets can also be used.

**Figure 6**

Figure 6 schematically shows a tensile tester for establishing the crushing strength of a tablet. This figure is a schematic side view of a LR5K Plus tensile tester (available from Lloyd Instruments, UK), with a load cell 400, to test the crushing strength of a tablet 30. For this, the tablet 30 is being subjected to a load force with rod 401 while it rests on support 300.

**Figure 7**

In figure 7 a package 500 containing a tablet according to the invention is schematically shown. Package 500 comprises a rectangular base and multiple blisters 501 having contained therein tablets 30. The blister package can be of the peel-off type, wherein a layer (not shown) fixed to the rectangular base can be peeled off to open each one of the blister to take the respective tablet out. Also, in particular when the mechanical stability of the tablet is sufficient, the layer can be of a more conventional type (often aluminum foil) wherein each tablet is pushed through the layer.

**Figure 8**

Figure 8 schematically shows an alternative device to establish the mechanical stability of an ODT. With this device the propensity of freeze dried tablets to remain intact after being pressed through a foil. Dies 3001 and 3002 are units that contain cylindrical holes of 13 diameter. An aluminium foil 3005 with a thickness of 5 \mu m is placed between the dies and covered by a rubber ring 3003 to prevent movement of foil. A freeze dried tablet 30 is placed on the foil and can be pressed through the foil using a glass rod 4001 by exerting a manual force on the rod. After pressing tablets through the foil, either
complete tablets or fragments of tablets can be collected below die 3002.

Figure 9

Figure 9 shows examples of tablets or fragments of tablets after performing the test to measure the propensity to remain in tact after being pressed through a foil. Figure 9a shows tablets 30 that remain intact when being pressed through a 5µm foil. Figure 9b shows tablets 30° that are fragmented when being subjected to the same test.

Example 1

To obtain tablets containing a vaccine component, live human infectious influenza virus is harvested from eggs. The allantois fluid containing the virus is mixed with a stabilizer. The stabilizer is known from WO2006/094974 A2, and in particular described in Table 5 of that patent application (with a glycine content of 160g/l). The method of adding the stabilizer is also described in that patent application, namely in the general outline of the introductory part of the "Examples" section on page 24.

A plate is used having three rows of cavities according to figure 1b. In each of these cavities about 100µl of fluid formulation is dispensed in approximately 0.3 seconds. The formulation will start the freeze immediately upon contacting the cavity wall. However, it takes approximately 15 seconds before the pellet is substantially frozen such that it can be mechanically handled. After this, the pellets (which have a diameter of approximately 5.7 mm) are pushed out of the cavities (as explained in conjunction with figures 2 and 3) and transferred to freeze-dry container 15.

The frozen pellets (having a temperature of about minus 45°C) are arranged in the container 15 in the form of a packed bed with an aspect ratio of about 15. Multiple containers are then put in the lyophiliser (see figure 5) which has beforehand been brought to a temperature of about -35°C. The lyophiliser is subjected to the following freeze-drye cycle (Table 1).
As can be seen in Table 1, after loading the shelves with the filled containers the shelves are firstly kept at a temperature of -35°C for 30 minutes (the "Freezing" phase). Herewith the frozen pellets are brought to a temperature of -35°C. The pressure is kept atmospheric. Then, the temperature of the shelves is stabilized at -35°C during 20 minutes, pressure is still atmospheric ("Preparation"). Then, the pressure is lowered to 0.370 mbar in a period of ten minutes, the temperature of the shelves is kept at -35°C ("Initial sublimation"). Under these conditions, the frozen liquid already sublimes and heat is supplied to the pellets by the two heat sources via conduction and irradiation respectively. However, the speed of sublimation under these conditions is relatively low. To increase the speed of sublimation, the shelves are brought to a temperature of 40°C in a period of 3 hours ("Sublimation 1"), and kept at that temperature for 16 hours ("Sublimation 2"). The pressure is kept at the low value of 0.370 mbar. Thereafter, the pressure is further reduced to 0.021 mbar whilst the temperature of the shelves is brought to 4°C. This latter step takes 1 minute ("Closing step"). After that, the sublimation process is completed and about 98% of the frozen liquid has left the pellets, thereby transforming into fast-disintegrating tablets. Then, dried nitrogen gas with a temperature of about 20°C is led into the lyophiliser until the pressure is about atmospheric. This takes about 2 minutes. Then the door can be opened to take out the tablets. When using the present method, it can be seen that a homogenous lyophilising result can be obtained, visible as a homogenous bed of lyophilized pellets. After opening the lyophiliser, the tablets are preferably not subjected to a humid environment to try and prevent condensation of water on the tablets. In particular, the tablets are filled in containers in a closet with an atmosphere of dried air or nitrogen. After filling the containers, they are closed and stored in a cool place (4-8°C) until further use.

<table>
<thead>
<tr>
<th>Phase</th>
<th>Time [h:m]</th>
<th>Temp [°C]</th>
<th>Vacuum [mbar]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freezing</td>
<td>00:30</td>
<td>-35</td>
<td>1000</td>
</tr>
<tr>
<td>Preparation</td>
<td>00:20</td>
<td>-35</td>
<td>1000</td>
</tr>
<tr>
<td>Initial sublimation</td>
<td>00:10</td>
<td>-35</td>
<td>0.370</td>
</tr>
<tr>
<td>Sublimation 1</td>
<td>03:00</td>
<td>40</td>
<td>0.370</td>
</tr>
<tr>
<td>Sublimation 2</td>
<td>16:00</td>
<td>40</td>
<td>0.370</td>
</tr>
<tr>
<td>Closing step</td>
<td>00:01</td>
<td>4</td>
<td>0.021</td>
</tr>
</tbody>
</table>

Table 1
This way, lyophilized spherical tablets can be obtained with an average diameter of approximately 5½ mm and having contained therein a live vaccine ingredient.

The tablets can be used to provide a pharmaceutical pack. This pack consists of a container (such as a glass or plastic vial) containing one or more of the tablets and optionally other constituents. The vaccine ingredient in the tablets can be administered to a human subject by placing one tablet under the tongue of the patient and leave the tablet to melt. The live influenza virus will enter the patient's body tissue via the mucosa.

**Example 2**

To obtain tablets containing a chemical drug a plate can be used having three rows of cavities according to figure 1C. In each of these cavities about 500 µl of fluid formulation is dispensed in approximately 2 seconds. At this dosing speed the cavity wall is completely wetted and thus the surface of the part of the pellet that is in the cavity (before the pellet is taken out of the cavity) is a negative print of the surface of the cavity, in this case a smooth surface without indentations or wrinkles. If a logo (either positive or negative) would have been present in the cavity, that logo would have been visible on the surface of the pellet. Examples of fluid formulations which can be used to make frozen pellets are given here-beneath:

**Fluid formulation 1:** 2 weight percent asenapine ((3aS,12bS)-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1/-/-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate (1:1); ORG 5222), 4 weight percent hydrolyzed gelatin (available from Croda, Yorkshire, England), 3 weight percent mannitol (PEARLITOL®, type C160, available from Roquette, Lestrem, France), and water QS (*quantum sufficiat, i.e. added to complete 100% total weight).*

**Fluid formulation 2:** 16 weight percent SCH 530348 bisulfate thrombin receptor antagonist (TRA; see US 7,235,567), 3.5 weight percent hydrolyzed gelatin, 3 weight percent mannitol, 3.73 weight percent sodium citrate dihydrate, 1.41 weight percent citric acid monohydrate, and water QS.

**Fluid formulation 3:** 8 weight percent TRA, 8 weight percent gelatin (Sol P, available
from Gelita, Eberbach, Germany), 9 weight percent mannitol, 3.73 weight percent sodium citrate dihydrate, 1.41 weight percent citric acid monohydrate, and water QS.

5 Fluid formulation 4: 8 weight percent TRA, 8 weight percent gelatin (Sol P, available from Gelita, Eberbach, Germany), 9 weight percent mannitol and water QS.

The formulation will start to freeze immediately upon contacting the cavity wall. However, it takes approximately 45 seconds before the pellet is substantially frozen such that it can be mechanically handled. After this, the pellets (which have a diameter of approximately 9.8 mm) are pushed out of the cavities (as explained in conjunction with figures 2 and 3) and brought over in freeze-dry container 15.

The frozen pellets (having a temperature of about minus 45°C) are arranged in the container 15 in the form of a densely packed monolayer. Multiple containers are then put in the lyophiliser (see figure 5) which has beforehand been brought to a temperature of about -35°C. The lyophiliser is subjected to the following freeze-drye cycle (Table 2).

<table>
<thead>
<tr>
<th>Phase</th>
<th>Time [h:m]</th>
<th>Temp [°C]</th>
<th>Vacuum [mbar]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freezing</td>
<td>00:30</td>
<td>-35</td>
<td>1000</td>
</tr>
<tr>
<td>Preparation</td>
<td>00:30</td>
<td>-35</td>
<td>1000</td>
</tr>
<tr>
<td>Initial sublimation, part 1</td>
<td>00:10</td>
<td>-35</td>
<td>0.310</td>
</tr>
<tr>
<td>Initial sublimation, part 2</td>
<td>05:00</td>
<td>-15</td>
<td>0.310</td>
</tr>
<tr>
<td>Sublimation 1</td>
<td>07:00</td>
<td>10</td>
<td>0.310</td>
</tr>
<tr>
<td>Sublimation 2</td>
<td>24:00</td>
<td>35</td>
<td>0.310</td>
</tr>
<tr>
<td>Closing step</td>
<td>00:01</td>
<td>35</td>
<td>0.310</td>
</tr>
</tbody>
</table>

As described here-above, after the "Closing step", the sublimation process is completed and about 98% of the frozen liquid has left the pellets, thereby transforming into fast-disintegrating tablets. Then, dried nitrogen gas with a temperature of about 20°C is led into the lyophiliser until the pressure is about atmospheric. This takes about 2 minutes. Then the door can be opened to take out the tablets. The tablets are filled in containers in a closet with an atmosphere of dried air or nitrogen. After filling the containers, they are closed and stored in a cool place (4-8°C) until further use.
The disintegration of the resulting tablets can be tested by putting a tablet in a beaker filled with water having a temperature of 37°C, and measuring how long it takes before the tablet is in essence fully disintegrated (no large pieces visible with the naked human eye). It appears that all tablets made with the fluid formulations 1, 2, 3 and 4 disintegrate within 5-10 seconds.

**Example 3**

In this example various methods to assess the mechanical stability of a tablet are described. The first test is a tablet friability test which is commonly used for testing the vulnerability of tablets towards mechanical handling. An apparatus and method to unambiguously assess this friability is available from DeltaLab, Moirans of France: the A41 13 Tablet Friability and Abrasion Tester. Other apparatus and methods are commercially available as well.

A method for assessing another property that may be used to characterize the mechanical stability of a tablet is establishing the crushing strength of a tablet. The principle of this testing method is that a strain is put on a tablet and the resulting force is measured until the tablet is completely crushed. For this a LR5K Plus tensile tester of Llyod Instruments (Fareham, Hants, UK) can be used. In the present example we used the XLC 5ON load cell (see figure 6). The punch displacement (also called "extension") speed was 10 mm/min. Force-displacement profiles were detected in three-fold and breakage patterns were determined with Nexxygen software which has been supplied with the tester. It is noted that as an alternative, the crushing strength could be measured with the Pharmatest PTB 300/301 (available from Pharmatest, Hainburg, Germany).

In a first experiment a series of 250μl spherical placebo tablets (containing no medicinal substance) has been made with a method as described here-above (Example 2), differing however in the size of the cavities: the radius is 3.9 mm and the depth is 3.0 mm. Various fluid formulations were used, each comprising a different amount of the gelator Gelita Sol P (Gelita, Eberbach, Germany) and crystalline carrier mannitol (PEARLITOL®, type C160, obtained from Roquette, Lestrem, France) to arrive at various different tablets. Apart from these compounds the fluid formulations comprised water. In table 5 the various compositions are shown.
When a tablet is being assessed for its crushing strength with the Llyod Instruments LR5K tensile tester, firstly the load is increased with the extension. After some time, when the tablet fails (i.e. breaks), the increase of the load stops or even decreases. The maximum load at the time of failure is called the crushing strength. The results of the measurements of the crushing strengths of the tablets are depicted in Table 6.

### Table 5

<table>
<thead>
<tr>
<th>Batch</th>
<th>gelatin (w %)</th>
<th>mannitol (w %)</th>
<th>water QS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sol P1</td>
<td>4</td>
<td>3</td>
<td>93</td>
</tr>
<tr>
<td>Sol P2</td>
<td>4</td>
<td>6</td>
<td>90</td>
</tr>
<tr>
<td>Sol P3</td>
<td>4</td>
<td>9</td>
<td>87</td>
</tr>
<tr>
<td>Sol P4</td>
<td>8</td>
<td>3</td>
<td>89</td>
</tr>
<tr>
<td>Sol P5</td>
<td>8</td>
<td>6</td>
<td>86</td>
</tr>
<tr>
<td>Sol P6</td>
<td>8</td>
<td>9</td>
<td>83</td>
</tr>
<tr>
<td>Sol P7</td>
<td>12</td>
<td>3</td>
<td>85</td>
</tr>
<tr>
<td>Sol P8</td>
<td>12</td>
<td>6</td>
<td>82</td>
</tr>
<tr>
<td>Sol P9</td>
<td>12</td>
<td>9</td>
<td>79</td>
</tr>
</tbody>
</table>

What can be seen is that the average crushing strength is relatively high for these
tablets (which are all based on fluid formulation comprising 3 or more weight percent of a crystalline carrier and 4 or more weight percent of a gelator).

In a second experiment a series of 500 µl oblate tablets, optionally containing TRA (as mentioned under Example 2) as medicinal substance, has been made with a method as described here-above (Example 2), differing however in the size of the cavities: the radius is 12.0 mm and the depth is 3.0 mm. Various fluid formulations were used, each comprising a different amount of the gelator Gelita Sol P (Gelita, Eberbach, Germany) and crystalline carrier, composed of various amounts of mannitol (PEARLITOL®, type C160, obtained from Roquette, Lestrem, France) and sucrose (α-D-glucopyranosyl-β-D-fructofuranoside). Apart from these compounds the fluid formulations comprised water QS. In table 7 the various compositions are shown.

Table 7

<table>
<thead>
<tr>
<th>Batch</th>
<th>gelatin (w %)</th>
<th>mannitol (w %)</th>
<th>sucrose (w%)</th>
<th>TRA (w%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>K</td>
<td>8</td>
<td>9</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>L</td>
<td>8</td>
<td>9</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>M</td>
<td>8</td>
<td>12</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>N</td>
<td>8</td>
<td>12</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>O</td>
<td>8</td>
<td>9</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>P</td>
<td>8</td>
<td>12</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>

It appeared that the crushing strength of each of the tablets was the same, about 5N. This means that the additional sucrose nor the medicinal substance have a significant influence on the strength of the tablets in this experiment. The amount of 8 weight percent gelatin and over 9 weight percent mannitol therefore, which was found to give a very good crushing strength in the first experiment, appears to be very suitable for a tablet, in particular for a tablet that needs to have a high mechanical stability per se.

Example 4

The propensity of tablets to remain intact after being pressed through a foil has been determined using the device as described in conjunction with figure 8. This test is
referred to as the "push through test" in this example. Tablets of different compositions were produced. Amounts and ratios of two types of gelatin were varied to obtain a gelator, in line with data published by Chandrasekhar, R., Hassan, Z., Al-Husban, F, Smith, A.M and Mohammed, A.R. Eur. J. Pharm. Biopharm 72 (2009) 119-129. Two types of gelatin were used: Sol P (a non gel-forming gelatin) and BS100 (a gel-forming gelatin). The latter gelatin is available from Gelita, Eberbach Germany. The amount of mannitol (PEARLITOL®, type C160), was kept at two levels. All tablets contained 2% (m/v) of a drug, in this case asenapine (see Example 2). Oblate, spherical and flat tablets with a volume of 250 μl were made and were tested in the push through test. For comparison, a commercially available 250 μl tablet ("Tablet") was also tested. This tablet contained 2% of a drug, 4% of an unknown type of gelator and 3% mannitol. After testing, tablets were either intact or fractured into numerous pieces, which is illustrated by the schematic drawings in figure 9. Table 8 summarises the results and presents the percentage of tablets intact when 10 tablets of each composition and specific shape and volume were tested. It is noted that ODT’s are in general so friable that it is commonly understood that no tablets will remain intact in the chosen set-up. Surprisingly however, it was found that using the present invention, tablets can be made that remain intact when being pressed through a 5μm thick aluminium foil.

The results in table 8 also imply an effect of the shape of the tablet to survive the push through test. The oblate and spherical shapes in general seem to be superior compared to flat tablets. It is possible to express surface curvature of the upper or lower surface relative to the diameter of the unit. The dosing principle of the method according to the invention, together with the fact that the liquid dosed has a certain surface tension implies that the surfaces of the tablet can be described as two hemispheres in the case of spherical tablets and two connected spherical caps in the case of oblate tablets. For reason of the fact that the pellets shrink during freeze drying or during storage, or both, the dosing volume is not an adequate prediction of the future dimensions of the tablets. It is possible to calculate the radius of curvature of the cap and correlate that to the diameter of the tablet using the dimensions of the tablet, using widely available information that correlates dimensions of a cap with its volume. For example, the relative curvature \( K \) of the tablet is defined by the ratio of the radius of curvature \( R \) of the cap and half the diameter of the tablet \( D \):

\[
K = \frac{R}{D/2}
\]
Higher values of relative curvature are correlated with flatter surfaces. The spheres used in this test had a relative curvature $K$ of about 1.0. The oblates had a relative curvature $K$ of about 1.2, and the "tablets" had a relative curvature $K$ of indefinite magnitude. One may conclude that a value for $K$ between 1 and 1.2 is optimal.

Table 8

<table>
<thead>
<tr>
<th>Sample</th>
<th>Sol P (% w/v)</th>
<th>BS 100 (% w/v)</th>
<th>Mannitol (% w/v)</th>
<th>Shape</th>
<th>Percentage intact</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8</td>
<td>0</td>
<td>9</td>
<td>oblate</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
<td>9</td>
<td>0</td>
<td>sphere</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>oblate</td>
<td>100</td>
</tr>
<tr>
<td>0</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>sphere</td>
<td>100</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>oblate</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>oblate</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>sphere</td>
<td>40</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>oblate</td>
<td>40</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>8</td>
<td>sphere</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>8</td>
<td>tablet</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>oblate</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>3</td>
<td>sphere</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>3</td>
<td>tablet</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>oblate</td>
<td>0</td>
</tr>
<tr>
<td>&quot;Tablet&quot;</td>
<td>4*</td>
<td></td>
<td>3</td>
<td>tablet</td>
<td>0</td>
</tr>
</tbody>
</table>

* type of gelatin not known

In general, tablets with about 4% gelator seem to have a good resistance against fracture when being pushed through an aluminium foil. It was also found that the presence of at least 2 weight percent of a gel-forming gelatin (such as BS100) may lead
to tablets with a very good score in a push through test. This may be due to a higher "network" degree in these tablets. Tablets having a non gel-forming gelatin (such as Sol P) as additional compound in the gelator are however preferred, due to better disintegration properties.
CLAIMS

1. A process for the preparation of an orally disintegrating tablet for administration to a
human subject, the tablet containing a medicinal substance to treat a disorder of the
human subject, comprising the steps of:

- providing a fluid formulation comprising the medicinal substance,
- providing a solid element having formed therein at least one cavity,
- cooling the solid element to a temperature below a freezing temperature of the
  formulation,
- filling the cavity with the fluid formulation,
- solidifying the formulation while present in the cavity by extracting heat from the
  formulation through a cavity wall by conduction, to form a solid pellet comprising the
  medicinal substance without actively shaping the entire surface of the pellet,
- taking the pellet out of the cavity, and
- drying the pellet in a vacuum to obtain the tablet.

2. A process according to claim 1, characterised in that the volume of the cavity is
smaller than the volume of the pellet.

3. A process according to claim 2, characterised in that the volume of the cavity is
smaller than 50% of the volume of the pellet.

4. A process according to any of the preceding claims, characterised in that the
formulation comprises a crystalline carrier material that is solid at room temperature and
a gelator.

5. A process according to claim 4, characterised in that the formulation comprises 3 or
more weight percent of the crystalline material and about 4 weight percent of the
gelator.

6. A process according to any of the claims 4 or 5, characterised in that the gelator
comprises a non gel-forming material, preferably a collagen derived material.

7. A process according to claim 6, characterised in that the collagen derived material is
a gelatine having a weight average molecular weight of $2 \times 10^4$ g/mol.
8. A process according to any of the preceding claims, characterised in that the volume of the pellet is larger than a maximum volume of a free droplet of the fluid formulation at a temperature and pressure used when filling the cavity.

9. A process according to claim 8, characterised in that a speed at which the cavity is filled with the fluid formulation is chosen such that the surface of the part of the pellet that is in the cavity before the pellet is taken out of the cavity, is in essence a negative print of the surface of the cavity.

10. A process according to any of the preceding claims, characterised in that a measure is taken to support automatic detachment of the pellet from the cavity wall.

11. A process according to claim 10, wherein the cavity is formed in a solid element characterised in that the automatic detachment is supported by keeping the temperature of the solid element adequately beneath the freezing temperature of the fluid formulation.

12. A process according to any of the preceding claims, characterised in that the pellets are arranged in a heat conducting container having a bottom and side walls, and that a heat source is provided above a top layer of the packed pellets, the heat source having a surface directed to a top layer of the bed, which surface has an emissivity coefficient of at least 0.4, whereafter the pellets are subjected to the vacuum while at the same time heating at least the bottom of the container and the said surface to provide heat to the particles to support drying of the pellets.

13. An orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a disorder of the human subject, wherein the tablet is obtainable via a method according to any of the claims 1-12, characterised in that the tablet has a curved surface.

14. An orally disintegrating tablet according to claim 13, characterised in that the tablet has a relative curvature $K$ between 1 and 1.2.

15. A tablet according to any of the claims claim 13 and 14, characterised in that the tablet comprises a gelator comprising at least 2 weight percent of a gel-forming material,
preferably a collagen derived material.

16. A tablet according to any of the claims 13 to 15, characterised in that the gelator comprises a non gel-forming material, preferably a collagen derived material.

17. Package containing an orally disintegrating tablet for administration to a human subject, the tablet containing a medicinal substance to treat a disorder of the human subject, wherein the tablet is individually packed in a container, characterised in that the tablet is formed in a cavity using a method according to any of the claims 1 to 12, the cavity being different from the container in which the tablet is packed.
FIG. 9a

FIG. 9b
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC

PCT/EP2010/055682

A61K9/00 A61K9/20

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61J

Electronic database consulted during the international search (name of database and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 93/12770 A (PFIZER [US]) 8 July 1993 (1993-07-08) cited in the application</td>
<td>1-17</td>
</tr>
<tr>
<td></td>
<td>page 11, line 10 - line 23; example 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>claims 1-12; example 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>paragraphs [0051], [0076], [0080]; claims 1-26; examples 12-14</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C

See patent family annex

- Special categories of cited documents

- T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- X document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- Y document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

- K document member of the same patent family

Date of the actual completion of the international search

4 June 2010

Date of mailing of the international search report

10/06/2010

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel +31-70) 340-2040, Fax +31-70) 340-3016

Authorized officer

Konter, Jörg

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>
| X        | EP 0 450 141 A (NEOPHORE TECH INC [US] JANSSEN PHARMACEUTICA INC [US])
          | 9 October 1991 (1991-10-09)
          | cited in the application
          | column 6, lines 18-25; example 12
          | column 11, line 33 - column 12, line 22;
          | claims 1-17
          | 1-17                              |
| A        | WO 03/028619 A (MCNEIL PPC INC [US])
          | 10 April 2003 (2003-04-10)
          | page 28, line 22 - page 29, line 15
          | page 52, line 1 - line 8
          | page 57, line 18 - line 28
          | page 62, line 18 - page 63, line 14
          | page 32, line 7 - line 28; claims 1-137;
          | figures 26,27,44,45,47,55-63       | 1-17                              |
**INTERNATIONAL SEARCH REPORT**

Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CA 2124686 Al</td>
<td>08-07-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69211157 Dl</td>
<td>04-07-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69211157 T2</td>
<td>02-10-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 617613 T3</td>
<td>17-06-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0617613 Al</td>
<td>05-10-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2087558 T3</td>
<td>16-07-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 942937 A</td>
<td>17-06-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3020207 T3</td>
<td>30-09-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6511011 T</td>
<td>08-12-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 101139 A</td>
<td>28-02-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5516530 A</td>
<td>14-05-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 5382437 A</td>
<td>17-01-1995</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 2006057207 AI</td>
<td>16-03-2006</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019817 Dl</td>
<td>06-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019817 T2</td>
<td>05-10-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 0450141 T3</td>
<td>24-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 118096 A</td>
<td>12-07-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3303884 B2</td>
<td>22-07-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 903542 A</td>
<td>15-02-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5079018 A</td>
<td>07-01-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2461873 Al</td>
<td>10-04-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1635863 A</td>
<td>06-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1432378 Al</td>
<td>30-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2005504589 T</td>
<td>17-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA04002969 A</td>
<td>20-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005008696 Al</td>
<td>13-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003086973 Al</td>
<td>08-05-2003</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (April 2005)